NCT03231033View on ClinicalTrials.gov

Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 17, 2017

Primary Completion Date

April 2, 2019

Study Completion Date

April 2, 2019

Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
DRUG

Pioglitazone

Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03231033 - Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis | Biotech Hunter | Biotech Hunter